Citigroup Inc Reiterates “$10.00” Price Target for Atara Biotherapeutics Inc (ATRA)

Citigroup Inc set a $10.00 price objective on Atara Biotherapeutics Inc (NASDAQ:ATRA) in a research report report published on Thursday. The brokerage currently has a sell rating on the stock.

Other equities analysts have also issued reports about the company. Jefferies Group LLC set a $23.00 price target on Atara Biotherapeutics and gave the company a buy rating in a research note on Monday, December 12th. Canaccord Genuity set a $47.00 price target on Atara Biotherapeutics and gave the company a buy rating in a research note on Monday, December 12th. Finally, Zacks Investment Research raised Atara Biotherapeutics from a sell rating to a hold rating in a research note on Wednesday, January 4th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $24.00.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA) opened at 21.25 on Thursday. The company has a 50 day moving average of $16.27 and a 200 day moving average of $17.10. Atara Biotherapeutics has a 1-year low of $12.45 and a 1-year high of $25.73. The company’s market capitalization is $618.14 million.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Thursday, March 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.98) by $0.35. On average, analysts predict that Atara Biotherapeutics will post ($3.70) earnings per share for the current fiscal year.

Your IP Address:

In other news, CEO Isaac E. Ciechanover sold 4,800 shares of the company’s stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $13.66, for a total transaction of $65,568.00. Following the transaction, the chief executive officer now directly owns 555,044 shares of the company’s stock, valued at $7,581,901.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 30,800 shares of the company’s stock in a transaction that occurred on Friday, March 17th. The stock was sold at an average price of $19.38, for a total value of $596,904.00. Following the transaction, the chief executive officer now directly owns 725,951 shares in the company, valued at $14,068,930.38. The disclosure for this sale can be found here. Insiders have sold 133,195 shares of company stock worth $2,288,178 over the last ninety days. 16.10% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of the company. Franklin Street Advisors Inc. NC purchased a new position in shares of Atara Biotherapeutics during the third quarter worth $214,000. Capital Impact Advisors LLC purchased a new position in shares of Atara Biotherapeutics during the third quarter worth $299,000. Creative Planning purchased a new position in shares of Atara Biotherapeutics during the third quarter worth $213,000. Eagle Asset Management Inc. raised its position in shares of Atara Biotherapeutics by 0.8% in the third quarter. Eagle Asset Management Inc. now owns 980,673 shares of the company’s stock worth $20,976,000 after buying an additional 8,081 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its position in shares of Atara Biotherapeutics by 9.5% in the third quarter. Neuberger Berman Group LLC now owns 688,715 shares of the company’s stock worth $14,732,000 after buying an additional 59,595 shares during the last quarter. 77.48% of the stock is currently owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.